IP Holdings

Xylonix is a Singapore-based biotechnology company specializing in the development of first-in-class cancer immunotherapies using its proprietary onco-parthanatos technology. The company's lead candidate, 010DS-Zn, is a zinc-gamma-polyglutamic acid (Zn-gamma-PGA) compound designed to kill cancer cells and convert them into inflammatory antigens, thereby stimulating a robust anti-tumor immune response. Beyond oncology, Xylonix is exploring the application of its technology to treat post-recovery complications of COVID-19, such as multi-system inflammatory syndrome. The company's pipeline also includes XNX-C005D, a PARP modulator targeting breast and liver cancers. Xylonix aims to improve the efficacy and accessibility of immunotherapy through strategic industry collaborations and innovative translational research.